Your browser does not support JavaScript!
COVID-19 : Découvrez les Plans de Continuité d’Activité des entreprises de l’environnement
Logo de Labiotech.eu

Labiotech.eu Source d'actualité

Une actualité de Labiotech.eu a été ajouté(e)
Hier à 12:12
Novacyt Launches Two-Hour Coronavirus Test After FDA Approval
The French clinical diagnostics specialist Novacyt has announced FDA authorization for its fast and easily transportable test for the coronavirus disease COVID-19. The company is also rolling out the...
www.labiotech.eu
Une actualité de Labiotech.eu a été ajouté(e)
Hier à 08:34
Silence Therapeutics to Work With AstraZeneca in RNAi Deal Worth up to €1.8B
AstraZeneca is recruiting RNAi specialist Silence Therapeutics to develop treatments for cardiovascular, renal, metabolic, and respiratory diseases. RNA interference, or RNAi, is a relatively new...
www.labiotech.eu
Une actualité de Labiotech.eu a été ajouté(e)
Il y a 2 jours
DBV Technologies’ Peanut Allergy Treatment Hits FDA Setback
French biotech DBV Technologies’ bid for the US approval of a skin patch to treat nut allergies could be delayed as the FDA requested more information on the patch’s efficacy. Specifically, the FDA...
www.labiotech.eu
Une actualité de Labiotech.eu a été ajouté(e)
Il y a 3 jours
How Will We Be Treating Cystic Fibrosis 10 Years From Now?
Current treatments for cystic fibrosis are not suitable for all patients and have a limited effect on this life-threatening disease. But new advances in the field promise to overcome these hurdles....
www.labiotech.eu
Une actualité de Labiotech.eu a été ajouté(e)
Il y a 3 jours
Vaccitech’s Prostate Cancer Vaccine Shows Promise in Phase II
The UK immunotherapy company Vaccitech has announced promising initial results from a phase IIa trial of a therapeutic vaccine that could offer a new way to treat advanced prostate cancer. In the...
www.labiotech.eu
Charger plus d'actualités

Informations juridiques
SIREN / SIRET - DE Labiotech

Adresse
Berlin Berlin DE Allemagne